{"id":45216,"date":"2025-10-29T20:44:13","date_gmt":"2025-10-29T12:44:13","guid":{"rendered":"https:\/\/flcube.com\/?p=45216"},"modified":"2025-10-29T20:44:14","modified_gmt":"2025-10-29T12:44:14","slug":"gsk-reports-strong-q3-2025-results-beats-forecasts-with-8-revenue-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45216","title":{"rendered":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth"},"content":{"rendered":"\n<p>UK biopharma GlaxoSmithKline plc (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.<\/p>\n\n\n\n<p><strong>Specialty Medicines Portfolio Fuels Momentum<\/strong><br>The Specialty Medicines segment led the charge, expanding 16% YoY to GBP\u202f3.4\u202fbillion (USD\u202f4.5\u202fbillion). Within this portfolio, oncology sales surged 39% to GBP\u202f511\u202fmillion (USD\u202f680\u202fmillion), respiratory, immunology &amp; inflammation grew 15% to GBP\u202f954\u202fmillion (USD\u202f1.27\u202fbillion), and HIV drug sales rose 12% to GBP\u202f1.94\u202fbillion (USD\u202f2.58\u202fbillion). Vaccines sales edged up 2% YoY to GBP\u202f2.7\u202fbillion (USD\u202f3.6\u202fbillion), while General Medicines grew 4% to GBP\u202f2.5\u202fbillion (USD\u202f3.3\u202fbillion).<\/p>\n\n\n\n<p><strong>Key Product Performance in Q3 \u201925<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Shingrix (shingles vaccine)<\/strong> \u2013 sales up 13% to GBP\u202f830\u202fmillion (USD\u202f1.1\u202fbillion), with a modest slowdown in China.<\/li>\n\n\n\n<li><strong>Arexvy (RSV vaccine)<\/strong> \u2013 up 36% to GBP\u202f251\u202fmillion (USD\u202f334\u202fmillion), reflecting reduced demand in the U.S.<\/li>\n\n\n\n<li><strong>Nucala (asthma drug)<\/strong> \u2013 14% increase to GBP\u202f499\u202fmillion (USD\u202f664\u202fmillion).<\/li>\n\n\n\n<li><strong>Benlysta (lupus therapy)<\/strong> \u2013 17% rise to GBP\u202f447\u202fmillion (USD\u202f595\u202fmillion).<\/li>\n\n\n\n<li><strong>Jemperli (endometrial\u2011cancer drug)<\/strong> \u2013 79% jump to GBP\u202f230\u202fmillion (USD\u202f306\u202fmillion).<\/li>\n<\/ul>\n\n\n\n<p><strong>Guidance Revision<\/strong><br>The robust performance prompted GSK to lift its full\u2011year outlook. Revenue growth is now projected at 6\u20117% (up from 3\u20115%), core operating profit growth at 9\u201111% (up from 6\u20118%), and core earnings per share (EPS) growth at 10\u201112% (up from 6\u20118%).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/q3-2025-results-announcement.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of q3-2025-results-announcement.\"><\/object><a id=\"wp-block-file--media-b6909a11-c86c-46c1-bc86-b15c530750e1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/q3-2025-results-announcement.pdf\">q3-2025-results-announcement<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/q3-2025-results-announcement.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b6909a11-c86c-46c1-bc86-b15c530750e1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,278,184,914],"class_list":["post-45216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth\" \/>\n<meta property=\"og:description\" content=\"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T12:44:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T12:44:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth\",\"datePublished\":\"2025-10-29T12:44:13+00:00\",\"dateModified\":\"2025-10-29T12:44:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216\"},\"wordCount\":229,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2901-1.webp\",\"keywords\":[\"Finanical Reports\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45216#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45216\",\"name\":\"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2901-1.webp\",\"datePublished\":\"2025-10-29T12:44:13+00:00\",\"dateModified\":\"2025-10-29T12:44:14+00:00\",\"description\":\"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45216\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2901-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2901-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth - Insight, China&#039;s Pharmaceutical Industry","description":"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45216","og_locale":"en_US","og_type":"article","og_title":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth","og_description":"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.","og_url":"https:\/\/flcube.com\/?p=45216","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-29T12:44:13+00:00","article_modified_time":"2025-10-29T12:44:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth","datePublished":"2025-10-29T12:44:13+00:00","dateModified":"2025-10-29T12:44:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45216"},"wordCount":229,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp","keywords":["Finanical Reports","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45216#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45216","url":"https:\/\/flcube.com\/?p=45216","name":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45216#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp","datePublished":"2025-10-29T12:44:13+00:00","dateModified":"2025-10-29T12:44:14+00:00","description":"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that outpaced consensus estimates. Revenues climbed 8% year\u2011on\u2011year (YoY) to GBP\u202f8.5\u202fbillion (USD\u202f11.3\u202fbillion) in constant currency terms, underscoring the company\u2019s resilient growth trajectory.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45216"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45216#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp","width":1080,"height":608,"caption":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2901-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45216\/revisions"}],"predecessor-version":[{"id":45219,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45216\/revisions\/45219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45218"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}